Stockscreener 앱 받기
63.93
0.92%
0.58
전일 마감가:
$63.35
열려 있는:
$63.12
하루 거래량:
318.81K
Relative Volume:
0.92
시가총액:
$1.38B
수익:
$486.82M
순이익/손실:
$18.78M
주가수익비율:
77.96
EPS:
0.82
순현금흐름:
$100.45M
1주 성능:
-5.26%
1개월 성능:
+0.58%
6개월 성능:
+9.02%
1년 성능:
+0.13%
1일 변동 폭
$62.67
$64.38
1주일 범위
$62.60
$68.18
52주 변동 폭
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(218) 634-3500
주소
210 MAIN STREET WEST, BAUDETTE, MN
ANIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
63.93 | 1.37B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
Should I hold or sell ANI Pharmaceuticals Inc. stock in 2025Top Growth Entry Points To Watch Now - jammulinksnews.com
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET - GlobeNewswire
How strong is ANI Pharmaceuticals Inc. company’s balance sheetEntry Signal Tracker For Consistent Profits - jammulinksnews.com
ANI Pharmaceuticals Sets Q2 2025 Earnings Call Date: Key Executive Team to Present Financial Results - Stock Titan
How many analysts rate ANI Pharmaceuticals Inc. as a “Buy”Post Market Updates For Consistent Profits - jammulinksnews.com
What are ANI Pharmaceuticals Inc. company’s key revenue driversAdvanced Screener Planner For Consistent Profits - jammulinksnews.com
Lacklustre Performance Is Driving ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Low P/S - 富途牛牛
ANI Pharmaceuticals (NASDAQ:ANIP) shareholders are still up 107% over 5 years despite pulling back 4.3% in the past week - simplywall.st
ANI Pharmaceuticals (NASDAQ:ANIP) pulls back 4.3% this week, but still delivers shareholders strong 16% CAGR over 5 years - Yahoo.co
Does ANI Pharmaceuticals Inc. stock perform well during market downturnsEntry Signal Guidance With Proven Results - jammulinksnews.com
Real time scanner hits for ANI Pharmaceuticals Inc. explainedSmart Allocation Stock Pick Insights Gaining Interest - metal.it
ANI Pharmaceuticals Challenges Court Verdict on Royalty Payment Agreement - AInvest
ANI Pharmaceuticals to Challenge Court Verdict - The Globe and Mail
Can ANI Pharmaceuticals Inc. Rally Enough to Break EvenTrend Analysis for Safer Trades Gains Popularity - metal.it
Short Covering May Lift ANI Pharmaceuticals Inc. in Near TermSmart Trade Plans With Risk Protection Explained - metal.it
Why ANI Pharmaceuticals Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - beatles.ru
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals By Investing.com - Investing.com South Africa
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals - Investing.com Australia
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals - The Manila Times
CG Oncology Secures Major Legal Victory: Court Rules No 5% Royalties on Promising Bladder Cancer Drug - Stock Titan
Published on: 2025-07-29 19:34:49 - metal.it
Is ANI Pharmaceuticals (ANIP) a High-Probability Earnings Beat Candidate in Q2 2025? - AInvest
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release - Yahoo Finance
Published on: 2025-07-29 03:23:31 - metal.it
What makes ANI Pharmaceuticals Inc. stock price move sharplyHigh-margin investment plays - jammulinksnews.com
ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value (NASDAQ:ANIP) - Seeking Alpha
How does ANI Pharmaceuticals Inc. compare to its industry peersCapitalize on market shifts before others do - jammulinksnews.com
What are the latest earnings results for ANI Pharmaceuticals Inc.High-performance investment picks - jammulinksnews.com
How does ANI Pharmaceuticals Inc. generate profit in a changing economySkyrocketing returns - jammulinksnews.com
Is ANI Pharmaceuticals Inc. a growth stock or a value stockPhenomenal capital gains - jammulinksnews.com
What is the dividend policy of ANI Pharmaceuticals Inc. stockMaximize your portfolio’s earning potential - jammulinksnews.com
How ANI Pharmaceuticals Inc. stock performs during market volatility200 Percent Profit Outlook - metal.it
What analysts say about ANI Pharmaceuticals Inc. stockFree Trading Strategy Suggestions - PrintWeekIndia
ANI Pharmaceuticals Inc. Stock Analysis and ForecastBreakneck growth rates - PrintWeekIndia
Is ANI Pharmaceuticals Inc. a good long term investmentTurbocharged investment results - PrintWeekIndia
Is ANI Pharmaceuticals Inc. stock a growth or value playDynamic portfolio growth - jammulinksnews.com
ANI Pharmaceuticals stock holds steady as H.C. Wainwright maintains Buy rating - Investing.com Canada
ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial - Yahoo Finance
ANI Pharma stock drops on trial setback (ANIP:NASDAQ) - Seeking Alpha
What drives ANI Pharmaceuticals Inc. stock priceBreakthrough capital growth - jammulinksnews.com
ANI Pharmaceuticals Reports on NEW DAY Clinical Trial Results - TipRanks
ANI Pharmaceuticals reports mixed results from NEW DAY trial for DME - Investing.com Australia
ANI Pharmaceuticals reports mixed results from NEW DAY trial for DME By Investing.com - Investing.com South Africa
ANI Pharmaceuticals Announces Results from NEW DAY Clinical - GlobeNewswire
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) - Yahoo Finance
Clinical Trial Reveals ILUVIEN Cuts DME Treatment Burden: Patients Need Only 2.8 vs 7.5 Injections - Stock Titan
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.80%
자본화:
|
볼륨(24시간):